PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say

2010-12-12
(Press-News.org) SAN ANTONIO -- Results for testing breast tumors for HER2 (http://www.mayoclinic.com/health/breast-cancer/AN00495) proteins and genes is most often straightforward when one piece of tumor (a single tumor block) is analyzed. However, tumors can be diverse, and researchers at Mayo Clinic (http://www.mayoclinic.org/) found that HER2 results can vary in up to 10 percent of patients when several tumor blocks are analyzed.

This could have significant implications for patient treatment, say the researchers, who are presenting their findings at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (http://www.sabcs.org/).

In their study, the researchers found that while three independent teams of expert pathologists agreed most of the time on how slices from a single tumor block from a patient should be classified in terms of HER2 genes and proteins, a consensus was harder to reach when several blocks from the same patient were available for analysis.

In fact, the pathologists, from central laboratories at Mayo Clinic, the University of Southern California, and the University of Pittsburgh, found significant heterogeneity, or variability, between two tumor blocks taken from the same patient in 5 to 10 percent of cases. Most often, one tumor block showed a normal HER2 expression, while the second piece of tumor tested HER2+.

Researchers say these findings matter because women with HER2+ breast cancer can benefit from Herceptin (http://www.mayoclinic.com/health/drug-information/DR601547), a drug designed to shut down a powerful cancer growth pathway.

"Even among expert pathologists there can be disagreements about what a tumor is telling us, and that impacts the care our patients receive," says the study's lead investigator, Edith Perez, M.D. (http://mayoresearch.mayo.edu/staff/perez_ea.cfm), deputy director of Mayo Clinic Cancer Center (http://cancercenter.mayo.edu/) in Florida.

The findings suggest that patients with multiple tumor samples who test normal for HER2 in one block should consider having the other tumor sample tested, Dr. Perez says. Most oncologists take and store more than one tumor block from their patients, but it is not clear who would fund testing of the second tumor sample, she adds.

This analysis continues the investigation into the reliability of HER2 protein (immunohistochemistry) and gene (fluorescence in situ hybridization, or FISH) tests that Dr. Perez has led since 2001. She and her team published a study in 2002 that found the disagreement between local and central laboratories that analyze these tests was between 15 and 20 percent. Central laboratories process more than 100 patient tumors per year and local labs perform fewer than that amount.

In this study, Dr. Perez wanted to know whether pathologists in the central laboratory agree more often with each other than they do with pathologists at local laboratories.

All three teams of pathologists conducted a blinded review of samples from 389 patients who had been enrolled in three adjuvant clinical trials (N8931, BCIRG005, and BCIRG006) in which HER2 testing was performed by local and central laboratories to determine if patients were candidates for these studies. Each of the three central laboratories received at least six slides from a patient's tumor block that the laboratory used to retest HER2 gene and protein levels.

The goals were to analyze how often the two tests agreed with each other between the laboratories; determine whether an "adjudication" process could resolve cases that don't agree; ascertain whether two samples from the same tumor agreed with each other; and gauge the impact of anti-HER2 therapy (Herceptin) in patients with disputed results.

Researchers found that there was 92 percent agreement between the two tests.

Then, the pathologists met face to face to discuss the 8 percent of tumor samples that they did not initially agree on, and reached consensus on 96 percent of the HER2 protein tests and 97 percent of the gene tests. The disagreement most often occurred in HER2 tests that were borderline for the established threshold of HER2+ positivity, Dr. Perez says.

They then looked at 125 patients (in the group of 389) who had more than one tumor block available for analysis. They found that 5 to 10 percent of these samples had dissimilar protein and gene test results.

This variability was greater than suspected, she says. "Some people have reported heterogeneity to be only 1 percent."

The slices from a tumor that make up a tumor block are made very close to each other (a distance of 6 microns) and a second tumor block can be made in the same tumor but at a distance from the original tumor slice. Biological variability can exist within a tumor for a number of reasons, Dr. Perez says. "The stroma surrounding a tumor can have a different impact on growth proteins that are expressed in one part of a tumor, compared to another, and development of pathways that lead to HER2-positivity may not occur at the same time in a tumor."

Finally, the researchers looked at how patients with these dissimilar tumor blocks were treated. In most cases, these patients had been diagnosed as HER2 normal, but the second tumor block tested as HER2+. "These patients may not have been diagnosed correctly and that is a big issue," says Dr. Perez. "It suggests that when a second tumor block is available in patients who test normal, it could be tested to validate these results."

This finding helps explain why some breast cancer patients who had normal HER2 results but who were still treated with Herceptin responded well to the treatment, she adds. "This may dispel the notion that Herceptin may be of benefit in women with truly normal HER2 tumors."

And the disagreement seen throughout this study can also help explain some of the variability in results seen between central and local laboratories, Dr. Perez says.

"It is necessary for oncologists to continue to refine these tests and their analysis," she says. "That may mean some tests may be needed for multiple tumor blocks, or that pathologists may need to discuss borderline results for some patients."

### VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Edith Perez and other researchers presenting at San Antonio Breast Cancer Symposium, are available on the Mayo Clinic News Blog (http://newsblog.mayoclinic.org/2010/12/06/lymphedema-study/). These materials also are subject to embargo, but may be accessed in advance by journalists for incorporation into stories. The password is sanantonio1.

The study was funded by the National Cancer Institute and Genentech.

Investigators from the University of California, Los Angeles, Genentech, and the International Drug Development Institute in Belgium also participated in the study.

The authors declare no conflict of interest.

About Mayo Clinic

Mayo Clinic is a non-profit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit www.mayoclinic.org/about/ and www.mayoclinic.org/news.

END



ELSE PRESS RELEASES FROM THIS DATE:

Higher co-payments increase chance of early discontinuation of breast cancer therapy

2010-12-12
A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early stage breast cancer. Dawn L. Hershman, MD, associate professor of medicine and epidemiology and co-director of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at Columbia University, will be presenting detailed study results at The 33rd CTRC-AACR San Antonio Breast Cancer Symposium, a comprehensive scientific meeting ...

Depression drug may relieve pain from breast cancer treatment, U-M study finds

2010-12-12
ANN ARBOR, Mich. — A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center. The women in the study were taking aromatase inhibitors, a type of drug designed to block the production of estrogen, which fuels some breast cancers. About half of women taking these drugs experience aches and pains in their joints and muscles that cannot be adequately relieved by over-the-counter painkillers. Up to 20 ...

Ubiquitous sugar molecule could be key to repairing deep wound without scarring

2010-12-12
Blocking fragments of the sugar molecule hyaluronan that triggers inflammation could be the key to robust healing and less scarring in deep wounds, Canadian researchers reported at the American Society for Cell Biology's 50th Annual Meeting in Philadelphia. In laboratory rats, the small peptide, named 15-1, which blocks fragments of the ubiquitous sugar molecule, hyaluronan, promoted wound healing, minimized scarring and forged stronger new tissue. These effects did not occur in the untreated animals in the study, according to Cornelia Tölg, Ph.D., of the London (Ontario) ...

Pomegranate juice components inhibit cancer cell migration; in vivo testing planned

2010-12-12
Researchers at the University of California, Riverside (UCR), have identified components in pomegranate juice that seem to inhibit the movement of cancer cells and weaken their attraction to a chemical signal that has been shown to promote the metastasis of prostate cancer to the bone, according to a presentation today at the American Society for Cell Biology's 50th Annual Meeting in Philadelphia. The researchers in the UCR laboratory of Manuela Martins-Green, Ph.D., plan additional testing in an in vivo model for prostate cancer to determine dose-dependent effects and ...

Human spermatogonial stem cells become insulin-secreting pancreatic cells in lab

2010-12-12
Insulin-secreting pancreatic islet cells have been generated from human spermatogonial stem cells (SSCs) directly isolated from human testicular tissue, researchers reported today at the American Association of Cell Biology 50th Annual Meeting in Philadelphia. When grafted into diabetic mice that lacked a transplant-rejecting immune system, the bioengineered cells functioned much like somatic β-islet cells, the Georgetown University (GU) Medical Center researchers said. By decreasing the animals' blood glucose levels, the human-derived islet cells demonstrated ...

'Grow your own transplant' may be possible for men with type 1 diabetes

2010-12-12
PHILADELPHIA – Men with type 1 diabetes may be able to grow their own insulin-producing cells from their testicular tissue, say Georgetown University Medical Center (GUMC) researchers who presented their findings today at the American Society of Cell Biology 50th annual meeting in Philadelphia. Their laboratory and animal study is a proof of principle that human spermatogonial stem cells (SSCs) extracted from testicular tissue can morph into insulin-secreting beta islet cells normally found in the pancreas. And the researchers say they accomplished this feat without use ...

Canadian scientists identify a spontaneously chain-reacting molecule

2010-12-12
In the burgeoning field of nano-science there are now many ways of 'writing' molecular-scale messages on a surface, one molecule at a time. The trouble is that writing a molecule at a time takes a very long time. "It is much better if the molecules can be persuaded to gather together and imprint an entire pattern simultaneously, by themselves. One such pattern is an indefinitely long line, which can then provide the basis for the ultimately thin molecular 'wire' required for nano-circuitry," says John Polanyi of the University of Toronto's Department of Chemistry, co- ...

Genetic variants linked to increased risk of common gynecological disease

2010-12-12
Research published today identifies two genetic variants that increase the risk of developing endometriosis, a common gynaecological disease. The study provides clues to the origin of this often very painful condition, which has a significant impact on the quality of life of sufferers. Details of the research, carried out at the Wellcome Trust Centre for Human Genetics and the Nuffield Department of Obstetrics & Gynaecology, University of Oxford; the Queensland Institute of Medical Research, Australia, and Brigham; and Women's Hospital and Harvard Medical School, Boston, ...

Demise of large satellite may have led to the formation of Saturn’s rings and inner moons

2010-12-12
Simulations performed at Southwest Research Institute may explain how Saturn's majestic rings and icy inner moons formed following the collision of a Titan-sized satellite with the planet, according to a paper published in Nature magazine's Dec. 12 Advance Online Publication. Saturn's rings are at present 90 to 95 percent water ice. Because dust and debris from rocky meteoroids have polluted the rings, the rings are believed to have consisted of pure ice when they formed. This composition is unusual compared to the approximately half-ice and half-rock mixture expected ...

Stem cells turned into complex, functioning intestinal tissue in lab

2010-12-12
CINCINNATI –For the first time, scientists have created functioning human intestinal tissue in the laboratory from pluripotent stem cells. In a study posted online Dec. 12 by Nature, scientists from Cincinnati Children's Hospital Medical Center say their findings will open the door to unprecedented studies of human intestinal development, function and disease. The process is also a significant step toward generating intestinal tissue for transplantation, researchers say. "This is the first study to demonstrate that human pluripotent stem cells in a petri dish can be ...

LAST 30 PRESS RELEASES:

These bacteria perform a trick that could keep plants healthy

Expanding the agenda for more just genomics

Detecting disease with only a single molecule

Robert McKeown recognized for a half century of distinguished service

University of Maryland awarded $7.8 million to revolutionize renewable energy for ocean monitoring devices

Update: T cells may offer some protection in an H5N1 ‘spillover’ scenario

Newborn brain circuit stabilizes gaze

Bats surf storm fronts during continental migration

Canadian forests are more prone to severe wildfires in recent decades

Secrets of migratory bats: They “surf” storm front winds to save energy

Early life “luck” among competitive male mice leads to competitive advantage overall

A closer look at the role of rare germline structural variants in pediatric solid tumors

Genetics of alternating sexes in walnuts

Building better infrared sensors

Increased wildfire activity may be a feature of past periods of abrupt climate change, study finds

Dogs trained to sniff out spotted lanternflies could help reduce spread

New resource available to help scientists better classify cancer subtypes

What happens when some cells are more like Dad than Mom

CAR-T cells hold memories of past encounters

Quantity over quality? Different bees are attracted to different floral traits

Cancer-preventing topical immunotherapy trains the immune system to fight precancers

Blood test can predict how long vaccine immunity will last, Stanford Medicine-led study shows

The nose knows: Nasal swab detects asthma type in kids

Knowledge and worry following review of standard vs patient-centered pathology reports

Cardiovascular disease and breast cancer stage at diagnosis

Herpes virus might drive Alzheimer's pathology, study suggests

Patients with heart disease may be at increased risk for advanced breast cancer

Chinese Medical Journal study reveals potential use of artificial intelligence (AI) in finding new glaucoma drugs

Genomic analysis of modern maize inbred lines reveals diversity and selective breeding effects

Research alert: Enzyme promoting tumor growth and spread in pancreatic cancer identified

[Press-News.org] Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say